STOCK TITAN
  1. Home
  2. Sec-filings
  3. NTHI
  4. [Form 4] NEONC TECHNOLOGIES HOLDINGS, INC. Insider Trading Activity

NeOnc Technologies (NTHI) CEO boosts stake with August open‑market buys

Filing Impact
(High)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported that CEO and director Thomas C. Chen, also a more-than-10% shareholder, purchased 36,259 shares of Class A common stock in open‑market or private transactions. He bought 33,787 shares at a weighted average price of $3.8477 on August 14, 2026, and 2,472 shares at $4.0445 on August 17, 2026, with actual trade prices in specified ranges. Positions reported also include indirect holdings such as 261,242 shares by HCWG LLC, 888,148 shares by NeuCen Biomedical Co. Ltd., 2,833,961 shares by T. R. Chen Third Family Limited Partnership, and 93,253 shares by the Tien Duan Chen Trust, with Chen disclaiming beneficial ownership of certain of these interests except to the extent of any pecuniary interest.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider CHEN THOMAS C
Role CEO
Bought 36,259 shs ($140K)
Type Security Shares Price Value
Purchase Common Stock F1, F3, F4 2,472 $4.0445 $10K
Purchase Common Stock F1, F2 33,787 $3.8477 $130K
holding Common Stock F5 -- -- --
holding Common Stock F6 -- -- --
holding Common Stock F7 -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 583,531 shares (Direct); Common Stock — 261,242 shares (Indirect, By HCWG LLC.); Common Stock — 888,148 shares (Indirect, By NeuCen Biomedical Co. Ltd.); Common Stock — 2,833,961 shares (Indirect, By TR Chen Third Family Limited Partnership.); Common Stock — 93,253 shares (Indirect, By Tien Duan Chen Trust.)
Footnotes (7)
  1. F1. The aggregate number of shares of Issuer's Class A common stock (the "Shares") purchased by the Reporting Person on the same day at different prices.
  2. F2. Represents the weighted average purchase price. The Shares were purchased at prices ranging from $3.2299 to $4.0993 per share, inclusive. Full information regarding the number of Shares sold at each price shall be provided to the Securities and Exchange Commission staff, Issuer or any security holder, upon request.
  3. F3. Represents the weighted average purchase price. The Shares were purchased at prices ranging from $4.04 to $4.1699 per share, inclusive. Full information regarding the number of Shares sold at each price shall be provided to the Securities and Exchange Commission staff, Issuer or any security holder, upon request.
  4. F4. Includes shares of common stock held by certain members of Reporting Person's immediate family of which Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest, if any, therein.
  5. F5. Such shares represent only Reporting Person's percentage interest in HCWG LLC.
  6. F6. Shares held by NeuCen Biomedical Co. Ltd. ("NeuCen"). NeuCen is owned in part by Reporting Person's spouse. Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any, therein.
  7. F7. Shares held by T. R. Chen Third Family Limited Partnership, a NV limited partnership, of which Reporting Person and his spouse are the general partners with sole voting and dispositive power. Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any, therein.
Total shares purchased 36,259 shares Aggregate open-market or private purchases reported for August 2026
Shares purchased on 2026-08-14 33,787 shares Common Stock, weighted average purchase price $3.8477 per share
Weighted average price on 2026-08-14 $3.8477 per share Purchases of Class A common stock on August 14, 2026
Shares purchased on 2026-08-17 2,472 shares Common Stock, weighted average purchase price $4.0445 per share
Weighted average price on 2026-08-17 $4.0445 per share Purchases of Class A common stock on August 17, 2026
HCWG LLC reported position 261,242 shares Indirect holding of Common Stock as of 2026-04-09, representing Chen’s percentage interest
NeuCen Biomedical Co. Ltd. reported position 888,148 shares Indirect holding of Common Stock with beneficial ownership disclaimed except for any pecuniary interest
T. R. Chen Third Family Limited Partnership position 2,833,961 shares Indirect holding of Common Stock with sole voting and dispositive power by Chen and spouse
weighted average purchase price financial
"Represents the weighted average purchase price. The Shares were purchased at prices"
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
pecuniary interest financial
"disclaims beneficial ownership except to the extent of his pecuniary interest"
disclaims beneficial ownership financial
"Reporting Person disclaims beneficial ownership of such shares except"
sole voting and dispositive power financial
"general partners with sole voting and dispositive power. Reporting Person"

FAQ

What insider purchases did NTHI CEO Thomas C. Chen report on this Form 4?
Thomas C. Chen reported purchasing 36,259 NTHI shares of Class A common stock. The trades were open‑market or private transactions executed on August 14 and 17, 2026, as disclosed in the Form 4 filing.

At what prices did Thomas C. Chen buy NTHI stock in August 2026?
Chen bought 33,787 NTHI shares at a weighted average $3.8477 on August 14, 2026, and 2,472 shares at $4.0445 on August 17, 2026. Actual trade prices were within specified ranges around those averages.

How many NTHI shares did Thomas C. Chen purchase on August 14, 2026?
On August 14, 2026, Chen purchased 33,787 shares of NTHI Class A common stock. The weighted average purchase price was $3.8477 per share, with individual trades occurring within a disclosed price range.

What indirect NTHI shareholdings associated with Thomas C. Chen are reported?
Reported indirect positions include 261,242 shares by HCWG LLC, 888,148 by NeuCen Biomedical Co. Ltd., 2,833,961 by T. R. Chen Third Family Limited Partnership, and 93,253 by the Tien Duan Chen Trust, with certain beneficial ownership disclaimed.

Does the Form 4 indicate Thomas C. Chen used a Rule 10b5-1 plan for these NTHI trades?
The filing’s Rule 10b5-1 checkbox is not marked as using a plan, and no footnote describes the trades as pursuant to a Rule 10b5-1 trading plan, based on the reported data.

How many total NTHI shares did Thomas C. Chen buy according to this Form 4?
Across the reported August 2026 transactions, Chen purchased 36,259 NTHI shares. This total combines 33,787 shares bought on August 14 and 2,472 shares bought on August 17, as summarized in the transaction data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CHEN THOMAS C
(Last)(First)(Middle)
23975 SORRENTO PARK
SUITE 205
(Street)
CALABASAS CALIFORNIA 91302
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
NEONC TECHNOLOGIES HOLDINGS, INC. [ NTHI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/14/2026P33,787(1)A$3.8477(2)581,059D
Common Stock08/17/2026P2,472(1)A$4.0445(3)583,531(4)D
Common Stock261,242(5)IBy HCWG LLC.
Common Stock888,148(6)IBy NeuCen Biomedical Co. Ltd.
Common Stock2,833,961(7)IBy TR Chen Third Family Limited Partnership.
Common Stock93,253IBy Tien Duan Chen Trust.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The aggregate number of shares of Issuer's Class A common stock (the "Shares") purchased by the Reporting Person on the same day at different prices.
2. Represents the weighted average purchase price. The Shares were purchased at prices ranging from $3.2299 to $4.0993 per share, inclusive. Full information regarding the number of Shares sold at each price shall be provided to the Securities and Exchange Commission staff, Issuer or any security holder, upon request.
3. Represents the weighted average purchase price. The Shares were purchased at prices ranging from $4.04 to $4.1699 per share, inclusive. Full information regarding the number of Shares sold at each price shall be provided to the Securities and Exchange Commission staff, Issuer or any security holder, upon request.
4. Includes shares of common stock held by certain members of Reporting Person's immediate family of which Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest, if any, therein.
5. Such shares represent only Reporting Person's percentage interest in HCWG LLC.
6. Shares held by NeuCen Biomedical Co. Ltd. ("NeuCen"). NeuCen is owned in part by Reporting Person's spouse. Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any, therein.
7. Shares held by T. R. Chen Third Family Limited Partnership, a NV limited partnership, of which Reporting Person and his spouse are the general partners with sole voting and dispositive power. Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any, therein.
Remarks:
/S/ THOMAS C CHEN08/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR